Tezepelumab is a human mAb that binds thymic stromal lymphopoietin (TSLP, an epithelial cell-derived cytokine that induces the production of Th2 cytokines, including IL-4, IL-5, and IL-13)62 used for the treatment of asthma. Here, IL4 is linked to asthma.